Levetiracetam Noridem (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilising neuronal membranes and reducing abnormal firing, it lowers neuronal excitability and helps prevent the spread of epileptic activity.

The dosage of Levetiracetam Noridem is determined by the prescribing clinician based on the patient’s age, weight, renal function and the severity of the seizure disorder. Only a qualified health professional should set the dosing regimen.

Levetiracetam is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies but limited human data. It is excreted in breast milk, so the benefits and risks should be discussed with a healthcare provider before use during pregnancy or lactation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levetiracetam has a unique mechanism targeting SV2A and does not require routine therapeutic drug monitoring, unlike many enzyme‑inducing antiepileptics such as carbamazepine. It is generally well tolerated, but clinicians consider individual seizure type, comorbidities and potential drug interactions when selecting therapy.

Store the product at ambient temperature, below 25 °C, in its original container. Protect it from moisture and direct sunlight. Do not freeze. Follow any additional handling instructions provided in the product label to maintain stability.

Levetiracetam Noridem is given by intravenous infusion. The infusion rate and duration are set by the treating physician, usually over 15 minutes to 30 minutes, depending on the clinical situation and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, blood dyscrasias, and emergence of suicidal thoughts or behavior. Patients should be monitored closely for any of these events, especially during the initial treatment period.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment who have not had dose adjustments, and for those with a history of serious psychiatric disorders without close monitoring.